Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, England, UK.
Faculty of Science and Engineering, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Value Health. 2024 Oct;27(10):1338-1347. doi: 10.1016/j.jval.2024.06.010. Epub 2024 Jul 8.
The Mount Hood Diabetes Challenge Network aimed to examine the impact of model structural uncertainty on the estimated cost-effectiveness of interventions for type 2 diabetes.
Ten independent modeling groups completed a blinded simulation exercise to estimate the cost-effectiveness of 3 interventions in 2 type 2 diabetes populations. Modeling groups were provided with a common baseline population, cost and utility values associated with different model health states, and instructions regarding time horizon and discounting. We collated the results to identify variation in predictions of net monetary benefit (NMB) and the drivers of those differences.
Overall, modeling groups agreed which interventions had a positive NMB (ie, were cost-effective), Although estimates of NMB varied substantially-by up to £23 696 for 1 intervention. Variation was mainly driven through differences in risk equations for complications of diabetes and their implementation between models. The number of modeled health states was also a significant predictor of NMB.
This exercise demonstrates that structural uncertainty between different health economic models affects cost-effectiveness estimates. Although it is reassuring that a decision maker would likely reach similar conclusions on which interventions were cost-effective using most models, the range in numerical estimates generated across different models would nevertheless be important for price-setting negotiations with intervention developers. Minimizing the impact of structural uncertainty on healthcare decision making therefore remains an important priority. Model registries, which record and compare the impact of structural assumptions, offer one potential avenue to improve confidence in the robustness of health economic modeling.
胡德山糖尿病挑战网络旨在研究模型结构不确定性对 2 型糖尿病干预措施成本效益估计的影响。
十个独立的建模小组完成了一项盲模拟练习,以估计两种 2 型糖尿病人群中三种干预措施的成本效益。建模小组获得了一个共同的基线人群、与不同模型健康状态相关的成本和效用值,以及关于时间范围和贴现的说明。我们汇总了结果,以确定净货币效益(NMB)预测的差异及其驱动因素。
总体而言,建模小组一致认为哪些干预措施具有正的 NMB(即具有成本效益)。尽管 NMB 的估计值存在很大差异,对于 1 种干预措施,差异高达 23696 英镑。差异主要是通过模型之间糖尿病并发症风险方程及其实施的差异驱动的。建模的健康状态数量也是 NMB 的一个重要预测因素。
这项研究表明,不同健康经济模型之间的结构不确定性会影响成本效益估计。尽管决策者可能会使用大多数模型得出类似的结论,即哪些干预措施具有成本效益,但不同模型产生的数值估计范围对于与干预措施开发者进行定价谈判仍然非常重要。因此,最大限度地减少结构不确定性对医疗保健决策的影响仍然是一个重要的优先事项。模型登记册记录和比较结构假设的影响,为提高健康经济建模稳健性的信心提供了一种潜在途径。